PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data
Moutafi M, Economopoulou P, Rimm D, Psyrri A. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data. Oral Oncology 2021, 117: 105292. PMID: 33862558, DOI: 10.1016/j.oraloncology.2021.105292.Peer-Reviewed Original ResearchMeSH KeywordsCisplatinHead and Neck NeoplasmsHumansPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesProgrammed Cell Death 1 ReceptorSquamous Cell Carcinoma of Head and NeckConceptsPoly (ADP-ribose) polymerase (PARP) inhibitorsCheckpoint inhibitorsCell death 1 (PD-1) checkpoint inhibitorsDeath-1 checkpoint inhibitorsDeath ligand 1 (PD-L1) expressionPARP inhibitorsPD-1 checkpoint inhibitorsNeck squamous cell carcinomaCornerstone of treatmentLigand 1 expressionImmune modulating effectsSquamous cell carcinomaSuccessful treatment outcomeDesign of trialsOutcome of therapyTreatment landscapeCell carcinomaNeck cancerTreatment outcomesClinical dataTherapeutic strategiesDNA damageRecent approvalImmune primingNucleotide excision repair